Dr. David H. Donabedian is Executive Partner and Interim NewCo CEO at Longwood Fund where he has led several portfolio companies as CEO from their founding until a permanent CEO is hired. Dr. Donabedian has over 25 years of professional experience and expertise leading business development and venture teams and has a demonstrated track record of company creation. He has served as co-founder, start-up CEO and/or Founding CEO of several Longwood-founded companies, including Solu Therapeutics, DEM BioPharma, ImmuneID, Axial Therapeutics, and was a founding executive of Alcyone Therapeutics.

Prior to joining Longwood, Dr. Donabedian held various leadership roles at biopharmaceutical companies including AbbVie and GlaxoSmithKline. At AbbVie, he served as Vice President and Global Head of Ventures and Early-Stage Collaborations where he led a global team that completed significant transactions across multiple therapeutic areas and stages of development. Prior to AbbVie, Dr. Donabedian served as Vice President of Global New Deal Strategy and Development at GlaxoSmithKline, Vice President of Business Development at Surface Logix (sold to Kadmon, acquired by Sanofi, for $1.9B), and Senior Manager at Accenture's Strategic Services Consulting Group.

Dr. Donabedian holds a B.A. in Chemistry from St. Anselm College, a Ph.D. in Polymer Chemistry from the University of Massachusetts Lowell, and an MBA from the University of North Carolina. He currently serves on the Board of Anuncia Medical and Alcyone Therapeutics.